Fulcrum Therapeutics FULC
NASDAQ FULC
$3.68 +0.00 (+0.00%)
As of: Oct 2, 2026 · 11:32 AM EDT

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2019 - 2021)

Updated

Fulcrum Therapeutics (FULC) recorded Non-Current Deffered Revenue of $1.49 million in Q1 2021, down 70.2% from $5.02 million a year earlier and down 49.7% from the prior quarter.

Analysis

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends

At the end of FY2020, Fulcrum Therapeutics reported Non-Current Deffered Revenue of $2.97 million, down 50.6% from FY2019.

  • Across earlier years, Non-Current Deffered Revenue came in at $6.01 million in FY2019.
  • Per Business Quant, the preceding three quarters came in at $2.97 million (Q4 2020), $5.97 million (Q3 2020) and $3.87 million (Q2 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Fulcrum Therapeutics 282.26 Mn 282.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 1.49 Mn
Dec 31, 2020 2.97 Mn
Sep 30, 2020 5.97 Mn
Jun 30, 2020 3.87 Mn
Mar 31, 2020 5.02 Mn
Dec 31, 2019 6.01 Mn
API Access

Fulcrum Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=FULC&period=max&api_key=YOUR_API_KEY